DiaMedica Therapeutics Inc. DMAC
Set alert
9.25 USD -0.27 -2.84%
At close · Oct 30
9.25 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
9.17 Day range 9.54
5.25 52-week range 10.42
- YTD
- +16.21%
- 1 year
- +32.14%
- Open
- 9.39
- Prev close
- 9.52
- Mkt cap
- 498.81M
- Vol
- 174.65K
- Avg vol
- 185.28K
- EPS
- -0.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.17
- High
- 9.54
- Forward P/E
- -7.26
- Beta
- 1.46
- Short ratio
- 3.88
- Inst. own
- 31.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 4.69
- 200-d avg
- 3.61
- 1y target
- 7.00
1M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
Key statistics
- Market cap
- 229.84M
- Enterprise value
- 122.45M
- Trailing P/E
- 0.00
- Forward P/E
- -7.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.00
- EPS (TTM)
- -0.56
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -11.14M
- Total cash
- 54.05M
- Total debt
- 388.00K
- Return on equity
- -35.18%
- Shares outstanding
- 42.76M
- Short % of float
- 0.59%
- 50-day average
- 4.69
- 200-day average
- 3.61
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 7.00 -24.3% downside
Now 9.25
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.1725.
Financials — quick view
DMAC Revenue — quarterly 0
DMAC Net income — quarterly -10.15M
DMAC EPS — quarterly -0.19
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.15 | -0.15 | 0.00 | 0.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.16 | -0.13 | +0.03 | +18.75% |
| Aug 7, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| May 8, 2024 | Mar 1, 2024 | -0.16 | — | — | — |
| Mar 19, 2024 | Dec 1, 2023 | -0.14 | -0.14 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 7, 2024 | HC Wainwright & Co. | init | — | Buy |
| Aug 16, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 21, 2024 | Craig-Hallum | main | Buy | Buy |
| Mar 21, 2024 | Oppenheimer | reit | Outperform | Outperform |
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- diamedica.com
News
- DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
- DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
- DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
- DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
- DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
- DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
- DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
- Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
- All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
- DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on DMAC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GIUFFRE RANDALL MICHAEL | Director | Stock Award(Grant) | Jan 1, 2024 | 411,194 |
| KELLEN SCOTT | Chief Financial Officer | Purchase | Jun 22, 2023 | 32,290 |
| KUNTZ RICHARD P | Director | Stock Award(Grant) | Jan 1, 2024 | 14,285 |
| PARSONS JAMES T CPA | Director | Stock Award(Grant) | Jan 1, 2024 | 59,937 |
| PAULS DIETRICH JOHN | Chief Executive Officer | Purchase | Jun 22, 2023 | 68,591 |
| PILNIK RICHARD D | Director | Stock Award(Grant) | Jan 1, 2024 | 278,602 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cooperman, Leon G. | 3.54% | 1,511,739 | 8.13M | Sep 29, 2024 |
| Vanguard Group Inc | 2.45% | 1,049,029 | 5.64M | Sep 29, 2024 |
| First Manhattan Co. LLC | 1.96% | 839,081 | 4.51M | Sep 29, 2024 |
| Paragon Associates & Paragon Associates Ii Joint Venture | 1.13% | 482,614 | 2.59M | Sep 29, 2024 |
| Bleichroeder LP | 0.89% | 382,317 | 2.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 306,958 | 1.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.75% | 747,198 | 4.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.59% | 253,733 | 1.36M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 149,057 | 801.18K | Oct 30, 2024 |
| Jacob Discovery Fd | 0.27% | 114,730 | 616.67K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.13% | 55,116 | 296.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 48,734 | 261.94K | Oct 30, 2024 |